APPLICATION
ANDA215827
TYPE
ANDA
ORIGINAL APPROVAL
2023-02-02
LATEST ACTION
2023-02-02
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
REGADENOSONPrescription
REGADENOSON 0.4MG/5ML (0.08MG/ML) · SOLUTION · INTRAVENOUS
Approval history
2023-02-02UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.